The commentary centers on a recent experimental study that took a bold, functionally oriented approach to a question that has long been addressed only through association. Rather than simply cataloging which bacterial species are more or less abundant in children with IgA vasculitis, the researchers asked whether the gut microbiota of these patients could actually transmit disease-relevant biological signals. To do so, they performed fecal microbiota transplantation from children with IgA vasculitis, with or without neurological involvement, into specific pathogen-free mice. This design allowed the investigators to test whether the microbial communities harvested from different patient subgroups carried distinct functional consequences when placed into a standardized animal host.

The results were striking. Mice that received microbiota from children with neurological involvement developed electroencephalographic abnormalities, while mice that received microbiota from children with IgA vasculitis but no neurological signs did not. In other words, the brain-wave disturbances appeared exclusively in the animals colonized with microbes from the neurologically affected donors. This is precisely the kind of outcome that moves a microbiome study from the descriptive realm into the experimental one. It suggests that something about the gut microbial composition of these particular patients, or the metabolites and immune signals that community produces, is capable of influencing neurophysiological function in a recipient organism.

What might that something be? The study pointed to several candidate mediators. The microbiota of neurologically affected children was enriched for Anaeroplasma, a genus of bacteria that has attracted growing attention in microbiome research. Alongside this microbial signature, the investigators detected alterations in short-chain fatty acids, a class of bacterial metabolites with well-documented effects on the immune system and the nervous system. Notably, caproic acid was increased. Short-chain fatty acids are among the most studied chemical messengers of the gut-brain axis: they can cross or modulate the blood-brain barrier’s environment, influence microglial behavior, and shape the differentiation of immune cells. The finding that a specific fatty acid profile accompanied the neurologically relevant microbiota provides a plausible biochemical bridge between gut and brain.

The immune dimension of the story is equally important. The study reported changes in systemic cytokines, including elevated levels of interleukin-17A and interleukin-1 alpha. Both are inflammatory signaling molecules with established roles in neuroinflammation and in the kind of small-vessel immune activation that defines IgA vasculitis itself. Interleukin-17A, in particular, is a hallmark cytokine of a T helper cell lineage that has been implicated in autoimmune and inflammatory diseases of the central nervous system. The convergence of a distinctive microbial genus, an altered metabolite landscape, and a shifted cytokine profile in the same patient subgroup forms what Xu describes as a gut-microbe-metabolite-immune-brain axis, a conceptual model in which each layer of the system could feed forward into the next.

This framework matters because the field of microbiome research has been criticized, fairly, for producing an abundance of correlational findings and a scarcity of causal ones. Hundreds of studies have reported that patients with a given disease harbor a different gut microbiota than healthy controls, but differences in composition do not by themselves establish that microbes drive disease. The commentary emphasizes that the value of the new study lies precisely in its functional experimental design: by transplanting the microbiota into mice and measuring physiological outcomes, the researchers generated evidence that goes beyond a list of differential taxa. Xu argues that integrating microbiome, metabolome, and immune profiling within such a functional framework is the way forward for the field, allowing investigators to move from association toward experimentally tractable hypotheses.

At the same time, the commentary is careful, and appropriately so, about the limits of causal interpretation. The number of donors involved was small, which means the findings could be vulnerable to individual variation and confounding. There was no paired human multi-omics validation, meaning the microbial, metabolite, and immune measurements were not comprehensively cross-validated within the same human cohort in a way that would lock the three layers of the axis together in patients themselves. And the neurophysiological changes observed in the mice were not fully resolved mechanistically; the study showed that brain activity was altered, but it did not pin down the precise cellular or molecular pathway by which the transplanted microbiota produced those alterations. These constraints do not invalidate the work, but they do mean that the results should be read as hypothesis-generating rather than as proof of causation.

The path forward, as Xu lays it out, involves two complementary strategies. The first is scale: larger human cohorts are needed to confirm that the Anaeroplasma enrichment, the caproic acid elevation, and the interleukin-17A and interleukin-1 alpha changes genuinely distinguish children with neurological involvement from those without, and to control for the many variables, from diet to antibiotics to disease activity, that can shape the gut microbiome in hospitalized children. The second is mechanistic depth: gnotobiotic models, in which mice are raised in sterile conditions and colonized with precisely defined microbial communities, would allow researchers to test whether individual bacterial species or defined consortia are sufficient to produce the electroencephalographic abnormalities, and to dissect the contribution of each metabolite and cytokine along the axis.

The broader significance of this work extends beyond a single rare complication of a single pediatric disease. IgA vasculitis has been the subject of earlier microbiome studies, which reported gut dysbiosis and shifts toward gram-positive organisms in affected children, but those studies were associative. The new work represents a template for how such associations can be converted into testable models: identify a clinically meaningful subgroup, transplant its microbiota into a controlled host, measure functional outcomes, and then layer on multi-omics profiling to identify candidate mediators. If this pipeline is validated, it could reshape how researchers approach not only IgA vasculitis but a range of inflammatory conditions in which neurological manifestations appear without a clear explanation.

For clinicians and families, the immediate practical implications remain limited; no microbiome-based diagnostic or therapy for neurological IgA vasculitis can be recommended on the basis of early animal work. But the conceptual payoff is real. A disease complication once viewed as an inexplicable vascular accident in the brain can now be framed as a potential disorder of communication between gut microbes, their metabolites, the immune system, and neural tissue. That reframing, as the commentary makes clear, is only the beginning. The hard work of proving the axis, identifying the responsible organisms and molecules, and translating those findings into biomarkers or interventions for children lies ahead. What the study offers today is something arguably more valuable than a premature conclusion: a rigorous, experimentally tractable set of hypotheses about how the gut may reach the brain in one of pediatric medicine’s most puzzling vasculitic syndromes.

Subject of Research: The role of the gut-brain axis, including microbiota, metabolites, and cytokines, in neurological involvement of pediatric IgA vasculitis.

Article Title: The gut-brain axis in IgA vasculitis with neurological involvement: from association to experimentally tractable hypotheses

Article References: Xu, Q. (2026). The gut-brain axis in IgA vasculitis with neurological involvement: from association to experimentally tractable hypotheses. Pediatric Research. https://doi.org/10.1038/s41390-026-05492-5

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05492-5

Keywords: IgA vasculitis, gut-brain axis, gut microbiota, fecal microbiota transplantation, short-chain fatty acids, caproic acid, Anaeroplasma, interleukin-17A, pediatric vasculitis, neuroinflammation, gnotobiotic mice, microbiome research

Bimekizumab represents a mechanistically distinct approach to psoriasis therapy. Where earlier biologics targeted single cytokines, bimekizumab is a monoclonal antibody that simultaneously neutralizes interleukin-17A and interleukin-17F, two closely related inflammatory signaling proteins that sit at the heart of the interleukin-23/T helper 17 axis driving psoriatic inflammation. Both cytokines are produced by activated T cells and other immune populations and act on keratinocytes, the dominant cell type of the epidermis, triggering the runaway proliferation, abnormal maturation, and recruitment of further immune cells that produce the thick, scaly plaques characteristic of the disease. Preclinical work has shown that interleukin-17F is co-expressed with interleukin-17A in psoriatic skin lesions, and that blocking both molecules suppresses downstream inflammatory gene expression more completely than blocking interleukin-17A alone. This dual inhibition is the theoretical basis for the exceptionally high clearance rates bimekizumab achieved in phase 3 randomized trials such as BE VIVID, BE READY, and BE SURE, where it outperformed both ustekinumab and secukinumab, a monoclonal antibody that targets only interleukin-17A.

Randomized controlled trials, however rigorous, enroll carefully selected patients under idealized conditions, and their populations often underrepresent the comorbidities, concomitant medications, and adherence patterns of everyday clinical practice. Real-world prospective studies fill that gap, and the new investigation, led by Manami Yoneyama and Teppei Hagino of Nippon Medical School Chiba Hokusoh Hospital together with colleagues at Nippon Medical School in Tokyo and the Fujimoto Dermatology Clinic in Funabashi, was designed to do exactly that. Between May 2022 and May 2025, the team prospectively followed 66 patients aged 15 years or older with moderate-to-severe plaque psoriasis who were treated with bimekizumab at a single center, assessing them repeatedly over two years with validated, site-specific scoring instruments rather than relying solely on whole-body measures.

The cohort was not selected for difficult-to-treat involvement, which makes the baseline data particularly informative. At the start of treatment, 58 of the 66 patients, or 87.9 percent, had scalp involvement; 42 patients, or 63.6 percent, had genital lesions; and 41 patients, or 62.1 percent, had nail disease. In other words, high-impact sites were the rule rather than the exception, mirroring the known epidemiology of psoriasis, in which genital involvement has been reported in a substantial proportion of patients and is frequently underdiagnosed because patients are reluctant to raise it with clinicians. Genital psoriasis in particular has been linked in prior research to marked impairment of quality of life and sexual functioning, while nail psoriasis can cause pitting, onycholysis, and functional disability of the hands, and scalp disease is a common source of visible flaking and social embarrassment.

The investigators scored each site with dedicated instruments. Genital lesions and fingernails were graded on physician’s global assessment scales, in which a score of zero indicates complete clearance, while the scalp was evaluated with the scalp-specific physician’s global assessment, or ss-PGA. The headline results at week 104 were striking: 77.8 percent of patients achieved complete clearance of genital psoriasis, 75 percent achieved a scalp-specific score of zero, and 44 percent achieved complete clearance of fingernail psoriasis. Nail disease is notoriously slow to respond to any therapy because the nail plate only reflects improvement as it grows out, so a 44 percent complete clearance rate at two years in an unselected real-world cohort is a meaningful result, even though nails remain the hardest of the three sites to clear.

Whole-body outcomes over the same period were robust and provide context for the site-specific figures. At week 104, 90.6 percent of patients had achieved a 75 percent reduction in their Psoriasis Area and Severity Index, or PASI 75; 71.9 percent achieved PASI 90; and 62.5 percent achieved PASI 100, meaning completely clear skin across the entire body surface. Even more telling, 93.8 percent of patients reached an absolute PASI score of two or lower, a threshold that many dermatologists now regard as the clinically relevant definition of minimal disease activity, since it accounts for how little disease a patient has rather than how much they improved from a high baseline. The parallel rise of the Dermatology Life Quality Index score of zero, achieved by 41.4 percent of patients at week 104, tracked closely with the clearance of genital and scalp lesions, reinforcing the argument that clearing these hidden sites is what translates biological improvement into a genuinely restored quality of life.

The study also captured a nuance that is often lost in headline efficacy figures. The achievement rates for genital, scalp, and nail clearance generally declined slightly during the second year, between week 52 and week 104, even though they remained high in absolute terms. The authors interpret this as a modest attenuation of effect during the later year of treatment rather than a loss of initial response, since the improvements established early were maintained through week 104. This pattern matters for clinicians and patients setting expectations: bimekizumab delivers rapid and deep clearance of difficult-to-treat sites in the first months of therapy, and the two-year data show that response is durable, but a small drift in the proportion of patients maintaining perfect clearance is observable over time in routine practice, where dosing intervals, concomitant illness, and other real-life factors differ from trial conditions.

The findings dovetail with the accumulating trial evidence for the drug. Two-year interim analyses from the open-label extension of the phase 3b BE RADIANT trial and the longer-term results from BE SURE and the extension of BE BRIGHT have already demonstrated that bimekizumab’s high skin clearance is sustained through two years in controlled settings, and pooled two-year analyses of phase 3 and 3b trials have specifically documented efficacy in high-impact areas including scalp, nail, and palmoplantar disease. What the new Japanese study adds is the first report of two-year outcomes for genital psoriasis with bimekizumab, a site for which such extended real-world data had not previously been published, together with confirmation that the drug performs well in a general clinic population rather than a curated trial cohort. Earlier work by the same group, including 24-week and 52-week real-world studies, had established the short-term signal; the present analysis extends that arc across a full two years.

For patients, the practical significance of these numbers is considerable. Genital psoriasis affects intimate relationships and self-image in ways that PASI scores barely capture, and the finding that more than three quarters of patients achieved completely clear genital skin at two years suggests that a substantial share of that hidden burden can be lifted and kept lifted. Scalp clearance at 75 percent and robust whole-body results at the same time point indicate that the dual interleukin-17A and interleukin-17F mechanism delivers consistent benefit across anatomically very different environments, from thin genital skin to thick scalp skin to the slow-growing nail unit. The study was conducted in accordance with the Declaration of Helsinki, approved by the institutional ethics committee, and carried out with informed consent from all participants, and the authors note that three of the investigators have received lecture fees from UCB, the drug’s manufacturer, while the remaining authors declare no conflicts of interest.

Caveats remain, as they do with any single-center observational study. There was no randomized comparator, the cohort of 66 patients is modest in size, and the slight second-year decline in clearance rates cannot be definitively attributed to any single mechanism without larger, controlled, multi-center data. Nevertheless, the study stands as the longest prospective real-world assessment of bimekizumab in genital, scalp, and nail psoriasis published to date, and it strengthens the case that dual blockade of interleukin-17A and interleukin-17F offers durable, site-specific clearance where patients need it most. As biologics with increasingly deep efficacy reshape the treatment goals of psoriasis from partial improvement to complete clearance, evidence that those goals remain achievable two years into routine clinical use, including in the regions patients find hardest to talk about, marks a genuine step forward in the care of this chronic immune-mediated disease.

Subject of Research: Long-term real-world effectiveness of bimekizumab for genital, scalp, and nail psoriasis

Article Title: Bimekizumab for the treatment of genital, scalp, and nail psoriasis: a 104-week real-world prospective study

Article References: Yoneyama, M., Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2026). Bimekizumab for the treatment of genital, scalp, and nail psoriasis: a 104-week real-world prospective study. Archives of Dermatological Research, 318(1), Article 417. https://doi.org/10.1007/s00403-026-04917-9

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04917-9

Keywords: psoriasis, bimekizumab, interleukin-17A, interleukin-17F, genital psoriasis, scalp psoriasis, nail psoriasis, biologics, real-world study, PASI, dermatology, quality of life

Bronchopulmonary dysplasia, or BPD, arises when the immature lungs of infants born at or before 32 weeks of gestation are injured by mechanical ventilation, oxygen therapy, and inflammation during a critical window of development. Instead of forming the millions of delicate alveolar sacs that allow efficient gas exchange, the lungs of affected infants develop simplified architecture with impaired blood vessel growth. The consequences can last a lifetime, ranging from repeated respiratory infections and asthma-like symptoms in childhood to reduced lung function in adulthood. Yet the disease is strikingly heterogeneous: some infants recover with minimal support while others remain dependent on intensive respiratory care well past their due date, and the biological reasons for this spectrum have remained poorly understood.

The research team, led by Saly N. Essoh, Fernando A. Munoz, and senior author Antonia P. Popova, hypothesized that the answer might lie in the very first days of life. They collected tracheal aspirates, fluid samples obtained during routine suctioning of breathing tubes, from 81 preterm infants who were mechanically ventilated for respiratory distress syndrome within their first week at the C.S. Mott Children’s Hospital Newborn Intensive Care Unit. Infants with congenital anomalies or neonatal sepsis were excluded. The researchers then measured a panel of pro-inflammatory cytokines and matricellular proteins, non-structural extracellular molecules that regulate interactions between cells and their surrounding matrix and modulate immune signaling, and compared the results with each infant’s eventual BPD outcome at 36 weeks postmenstrual age.

The severity classification followed the 2019 NICHD criteria, which grade BPD by the level of respiratory support an infant requires: no BPD if none is needed, grade 1 for low-flow nasal cannula oxygen, grade 2 for higher-flow oxygen or non-invasive positive pressure, and grade 3 for invasive mechanical ventilation. In the cohort, 36 infants had no BPD, 24 had grade 1, 8 had grade 2, and 13 had grade 3. Because of the smaller numbers in the two most severe categories and no significant protein differences between them, grades 2 and 3 were analyzed together. As expected, gestational age and birth weight fell with increasing severity, from a median of 28.7 weeks and 1,190 grams in infants without BPD to 25.9 weeks and 755 grams in the grade 2/3 group.

What emerged from the protein measurements was not one uniform inflammatory signature but three clearly separable patterns. The first pattern included cytokines elevated in BPD of any severity, most prominently interleukin-17A and its upstream regulator interleukin-23, along with TNF-alpha, IL-6, and the matricellular protein galectin 1. The second pattern was specific to grade 1 disease: IL-12p70, IL-12p40, the dendritic cell growth factor FLT3L, SPARC, and periostin were elevated only in infants who went on to develop mild BPD. The third pattern was the most surprising. In infants with grade 2/3 BPD, levels of thrombospondin 1, TGFBI, and CYR61, all matricellular proteins involved in angiogenesis and tissue repair, were lower than in infants with no BPD or mild disease, not higher.

Correlation analysis reinforced the idea that these proteins operate as coordinated networks. IL-17A and IL-23 moved together almost inseparably, with a correlation coefficient of 0.88, while IL-6 and TNF-alpha formed another tightly linked pair. FLT3L, IL-12p40, IL-12p70, and IL-2 formed a third cluster consistent with a dendritic cell-driven feedforward loop, and SPARC paired with periostin. Most intriguingly, the relationships of thrombospondin 1 to these networks shifted with disease outcome. In infants who never developed BPD, THBS1 correlated positively with IL-12p70. In the grade 1 group, it correlated negatively with the IL-12 family cluster. In the grade 2/3 group, it swung back to strong positive correlations with galectin 1, SPARC, TGFBI, and IL-5, suggesting that its biological role changes depending on the inflammatory context of the injured lung.

The predictive power of these measurements was striking. Using receiver operating characteristic analysis, the team found that a thrombospondin 1 cutoff of 3 nanograms per milliliter discriminated grade 2/3 BPD with 75 percent sensitivity and 86 percent specificity, yielding an area under the curve of 0.84. Infants with THBS1 below that threshold had a 7.3-fold higher risk of severe disease, a risk that remained 4.9-fold elevated after statistical adjustment for birth weight and sex. Periostin told the opposite story for mild disease: levels above 5.5 nanograms per milliliter identified grade 1 BPD with an area under the curve of 0.78, and the elevated risk of roughly threefold persisted after adjustment. Secretory component of immunoglobulin A, measured as a reference protein to confirm that differences were not due to sample dilution, was similar across all groups.

The biology behind these patterns may explain why low THBS1 is a red flag rather than a reassuring sign. Thrombospondin 1 is a key mediator of mechanotransduction, helping lung tissue adapt to mechanical stress, and experimental models show that its deficiency leads to impaired alveolar and vascular development, heightened inflammation, and worse injury. Notably, THBS1 deficiency has been shown to enhance IL-17A-driven inflammatory responses, providing a plausible mechanism by which low levels of the protein in the first week of life could permit unopposed IL-17 inflammation and fibrosis in the most severely affected infants. Periostin and SPARC, by contrast, regulate collagen assembly and tissue remodeling, and their selective elevation in grade 1 BPD may reflect a more contained, milder repair response, though the authors caution that in more severe disease these proteins may accumulate later or remain bound to the matrix, escaping detection in soluble airway samples.

The study carries important caveats. The cohort was modest in size, sample collection spanned 13 years, and not every infant was tested for every protein due to limited sample volumes. The cross-sectional design cannot establish causality, and the statistical thresholds have not yet been validated in an independent population. Tracheal aspirates, while a direct window into airway inflammation, may not capture immune activity in the lung interstitium or the systemic circulation. Still, the authors argue that the work lays a foundation for a new generation of early biomarkers. If confirmed in larger cohorts, a simple protein measurement in the first days of life could identify which ventilated preterm infants are destined for severe BPD, opening a window for targeted anti-inflammatory therapies or matricellular protein-based interventions before irreversible damage is done, and offering hope that the earliest molecular whispers of chronic lung disease can be heard, and answered, in time.

Subject of Research: Protein biomarkers in tracheal aspirates of preterm infants associated with bronchopulmonary dysplasia severity

Article Title: Pro-inflammatory and matricellular protein expression patterns associated with bronchopulmonary dysplasia severity

Article References: Essoh, S. N., Munoz, F. A., Christner, L. P., Cui, T. X., Zhang, Y.-J., Hershenson, M. B., & Popova, A. P. (2026). Pro-inflammatory and matricellular protein expression patterns associated with bronchopulmonary dysplasia severity. Pediatric Research. https://doi.org/10.1038/s41390-026-05584-2

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05584-2

Keywords: bronchopulmonary dysplasia, preterm infants, tracheal aspirate, thrombospondin 1, periostin, interleukin-17A, matricellular proteins, neonatal lung disease, biomarkers, pulmonary inflammation, tissue repair, Pediatric Research

Hepatocellular carcinoma remains one of the deadliest malignancies worldwide, ranking among the leading causes of cancer-related death. Its lethality stems largely from two clinical realities: a strong tendency to spread beyond the liver, and a stubborn resistance to conventional chemotherapeutic agents. Even as immunotherapy and targeted agents reshape the treatment landscape, many patients progress rapidly, and the molecular drivers of that progression have remained only partially mapped. The new findings add a critical piece to that map, positioning ApoA2 not as a passive biomarker but as an active participant in the tumor’s malignant behavior.

Apolipoproteins are best known for their role in lipid metabolism, shuttling cholesterol and triglycerides through the circulation. ApoA2 is a major constituent of HDL particles, and circulating levels of the protein have previously been associated with metabolic syndrome, cardiovascular disease, and, intriguingly, with altered risk profiles in several cancers. Epidemiological observations had hinted at connections between ApoA2 abundance and tumor behavior, but the mechanistic basis for such a link was unclear. The new study set out to determine whether ApoA2 is merely a correlate of disease severity or a genuine contributor to it.

Using hepatocellular carcinoma cell lines, animal models, and clinical tissue samples, the researchers found that ApoA2 expression is elevated in aggressive tumors and correlates with poor prognosis. When the team manipulated ApoA2 levels in laboratory models, the consequences were striking. Increasing ApoA2 enhanced the migratory and invasive capacity of cancer cells, while suppressing it markedly reduced metastatic potential. In mouse models of liver cancer, tumors with high ApoA2 activity spread more readily and responded poorly to chemotherapy, whereas lowering ApoA2 restored drug sensitivity and curtailed tumor dissemination.

The mechanistic heart of the paper lies in the HMGB1/IL-17A axis. HMGB1, or high-mobility group box 1, is a DNA-binding protein that normally resides in the nucleus, where it helps regulate gene expression and genome architecture. When cells are stressed, damaged, or activated by inflammatory signals, HMGB1 can be released into the extracellular space, where it acts as a danger signal, or alarmin, binding to receptors such as RAGE and Toll-like receptors to ignite inflammatory responses. The study demonstrates that ApoA2 promotes the secretion of HMGB1 from hepatocellular carcinoma cells, converting an intracellular housekeeping protein into an extracellular inflammatory messenger.

Once outside the cell, HMGB1 sets off a chain reaction. The researchers show that extracellular HMGB1 stimulates the production of interleukin-17A, a pro-inflammatory cytokine classically associated with Th17 immune cells but increasingly recognized as a product of the tumor microenvironment itself. IL-17A is known to fuel chronic inflammation, promote angiogenesis, and foster an immunosuppressive milieu that favors tumor growth. In this context, the ApoA2-HMGB1-IL-17A circuit appears to create a self-reinforcing inflammatory loop within and around the tumor, one that simultaneously drives cells toward invasive behavior and shields them from the cytotoxic effects of chemotherapeutic drugs.

The drug resistance component of the findings is particularly consequential. Chemotherapy for hepatocellular carcinoma has long been hampered by modest response rates, and understanding why some tumors shrug off treatment is a central question in the field. The study provides evidence that the HMGB1/IL-17A pathway activated by ApoA2 helps cancer cells survive drug-induced stress, likely through inflammatory survival signaling and alterations in the tumor microenvironment that blunt drug efficacy. When the researchers interfered with the axis, blocking HMGB1 or neutralizing IL-17A, the resistance phenotype weakened, suggesting that each node in the pathway represents a potential therapeutic target.

From a translational standpoint, the work carries several implications. First, ApoA2 could serve as a biomarker to identify patients whose tumors are predisposed to metastasis and treatment failure, allowing clinicians to stratify therapy more aggressively from the outset. Second, existing drugs or biologics that target IL-17A, some of which are already approved for inflammatory diseases such as psoriasis, could potentially be repurposed or adapted for hepatocellular carcinoma, either alone or in combination with chemotherapy or immunotherapy. Third, the identification of HMGB1 as a pivotal intermediary offers another intervention point, and HMGB1 inhibitors are an area of active pharmaceutical development.

The findings also resonate with a broader conceptual shift in cancer biology: the recognition that metabolic proteins and inflammatory circuits are deeply intertwined with malignant progression. Tumors do not evolve in isolation; they co-opt the body’s lipid transport machinery, danger-sensing systems, and immune signaling networks to advance their own agenda. The ApoA2/HMGB1/IL-17A axis is a vivid example of this co-option, linking a routine component of blood lipid particles to the inflammatory engine that powers metastasis and treatment resistance. It underscores why chronic inflammation of the liver, whether from viral hepatitis, alcohol, or fatty liver disease, creates such fertile ground for cancer, and why interrupting inflammatory signaling may be as important as attacking the cancer cells directly.

As with any preclinical study, important questions remain before the findings can change clinical practice. The precise molecular steps by which ApoA2 triggers HMGB1 release, the relative contributions of tumor cells versus immune cells to IL-17A production, and the safety of targeting this axis in patients with underlying liver disease all require further investigation. Human validation in large, prospective cohorts will be essential to confirm ApoA2’s prognostic value. Nevertheless, the study delivers a compelling and mechanistically grounded case that a familiar blood protein is an unexpected architect of liver cancer aggression, and it opens a concrete path toward therapies that could strip hepatocellular carcinoma of two of its most dangerous weapons: the ability to spread and the ability to survive treatment.

Subject of Research: The role of apolipoprotein A2 in promoting metastasis and drug resistance in hepatocellular carcinoma through the HMGB1/IL-17A inflammatory signaling axis.

Article Title: ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis

Article References: Fu, Z., Zhu, F., Fu, Z., Wang, C., Guan, T., Yuan, Y., Zhang, S., & Zhang, T. (2026). ApoA2 promotes tumor metastasis and drug resistance in hepatocellular carcinoma by activating the HMGB1/IL-17A axis. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03317-2

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03317-2

Keywords: ApoA2, hepatocellular carcinoma, HMGB1, interleukin-17A, metastasis, drug resistance, liver cancer, inflammation, tumor microenvironment, biomarker, cytokine signaling, chemotherapy

Insulin resistance is a central feature of metabolic syndrome and a powerful driver of type 2 diabetes and cardiovascular disease. In the modern antiretroviral therapy era, people living with HIV increasingly face a heightened burden of metabolic disorders, often at younger ages than the general population. While the shift to integrase strand transfer inhibitor-based regimens has dramatically improved viral suppression and drug tolerability, these regimens have also been linked to disproportionate weight gain and metabolic dysfunction, particularly among women. Understanding how sex, HIV, and related biological pathways interact to influence insulin resistance is therefore a pressing question for populations shouldering a dual burden of infectious and non-communicable diseases.

The research team recruited participants from the medical outpatient clinic between August 2023 and April 2024. People living with HIV had to have been on antiretroviral therapy for at least six months and achieved viral suppression, defined as a viral load below 50 copies per milliliter. Participants with conditions that could distort metabolic or inflammatory measurements, such as pregnancy, active malignancy, acute infections, or severe renal or hepatic disease, were excluded. After an overnight fast of eight to twelve hours, blood samples were collected and processed within two hours, with plasma and serum aliquots stored at minus 80 degrees Celsius until analysis.

In the laboratory, fasting glucose and lipid profiles were measured with automated clinical chemistry analyzers, while fasting insulin was quantified by immunoassay. HOMA-IR was calculated from fasting insulin and glucose values, with participants classified as insulin resistant at a threshold of 1.9 or above. The team also measured high-sensitivity C-reactive protein and interleukin-17A, a pro-inflammatory cytokine linked to Th17 immune responses, as well as angiotensin II, the primary effector peptide of the renin-angiotensin system, which has been implicated in promoting insulin resistance by interfering with insulin signaling and inducing oxidative stress in skeletal muscle and adipose tissue. All enzyme-linked immunosorbent assays were performed in duplicate with intra-assay coefficients of variation below 8 percent.

The cohort comprised 79 men and 154 women, with comparable median ages of roughly 48 years. Women carried a less favorable adiposity profile, with a higher mean body mass index of 26.9 versus 23.5 kilograms per square meter and larger waist circumferences of 88.3 versus 83.2 centimeters, indicating greater central obesity. Women also showed higher fasting insulin levels and higher HOMA-IR scores, together with a higher prevalence of insulin resistance at 17.5 percent compared with 12.7 percent in men. Inflammatory markers trended higher among women, although the variability was substantial, while men exhibited markedly higher alanine aminotransferase levels, hinting at sex-specific hepatic or metabolic stress.

The adjusted regression analysis for the overall population delivered two striking results. Female sex was independently associated with higher HOMA-IR, with a beta coefficient of 0.95 and a p-value of 0.037, while HIV-positive status was independently associated with lower HOMA-IR, with a beta of minus 1.54 and a p-value of 0.046. Hypertension, triglycerides, estimated glomerular filtration rate, angiotensin II, and interleukin-17A were not independently associated with insulin resistance in the combined model. The inverse HIV association was particularly pronounced among women, where HIV-positive status remained significantly linked to lower HOMA-IR after adjustment, with a beta of minus 2.31 and a p-value of 0.049.

Sex-stratified analyses revealed further divergence. Among men, hypertension was independently associated with higher HOMA-IR, with a beta of 0.61 and a p-value of 0.019, while higher estimated glomerular filtration rate was linked to lower insulin resistance, with a beta of minus 0.01 and a p-value of 0.029. This supports the well-established bidirectional relationship between hypertension and insulin resistance, in which insulin resistance promotes endothelial dysfunction, sympathetic nervous system activity, and oxidative stress, all of which can elevate blood pressure. The kidney finding suggests that impaired renal function, increasingly recognized as both a consequence and a contributor to insulin resistance through chronic inflammation, oxidative stress, and altered insulin clearance, may be an important metabolic correlate in men but not in women.

The authors caution that several findings warrant careful interpretation. Neither angiotensin II nor interleukin-17A was independently associated with HOMA-IR, a result that contrasts with experimental evidence implicating renin-angiotensin system activation and inflammatory pathways in insulin resistance. The researchers note that circulating biomarker concentrations may not fully capture tissue-level activity, and the cross-sectional design precludes any inference about temporal relationships. They also emphasize that the apparent sex differences were not formally tested for interaction, so statistical significance in one sex but not the other does not confirm true effect modification. The relatively small male subgroup of 79 participants may have reduced statistical power and produced less stable regression estimates.

The relatively low mean HOMA-IR values observed in this Zambian cohort also merit attention. Similar findings have been reported in other sub-Saharan African populations and may reflect differences in body composition, dietary patterns, physical activity, and genetic background compared with Western populations, where HOMA-IR thresholds of 2.5 to 3.0 are commonly applied. The authors suggest that thresholds derived from European and North American populations may not be directly applicable to African populations, underscoring the need for population-specific reference values in metabolic risk assessment.

Despite these limitations, the study offers a valuable exploratory framework for understanding sex-specific metabolic risk in African populations affected by HIV. The absence of data on physical activity, dietary intake, and menopausal status, particularly important given the median female age of 48 years, leaves open the question of whether the observed patterns reflect biological sex differences, lifestyle factors, hormonal status, or their interactions. The authors call for larger, adequately powered studies integrating comprehensive lifestyle, hormonal, inflammatory, and treatment-related assessments. In the meantime, the findings argue for incorporating sex-specific considerations into the assessment and management of insulin resistance, particularly in populations living with HIV, where metabolic risk pathways may diverge sharply between men and women.

Subject of Research: Sex differences in insulin resistance and associated metabolic and inflammatory markers among adults with and without HIV in Zambia

Article Title: Sex differences in insulin resistance and associated metabolic and inflammatory markers among adults with and without HIV in Zambia

Article References: Sibbenga, F., Chisompola, D., Chipuma, M., Chakulya, M., Lwiindi, P., Liamba, M. A., Hamooya, B. M., Povia, J. P., Liweleya, S., & Masenga, S. K. (2026). Sex differences in insulin resistance and associated metabolic and inflammatory markers among adults with and without HIV in Zambia. Physiological Reports, 14(17), Article e71093. https://doi.org/10.14814/phy2.71093

Image Credits: AI Generated

DOI: 10.14814/phy2.71093

Keywords: insulin resistance, HOMA-IR, HIV, Zambia, sex differences, hypertension, kidney function, angiotensin II, interleukin-17A, antiretroviral therapy, metabolic syndrome, inflammation